Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Sprott Physical Silver Trust Updates Its "At-the-Market" Equity Program
-
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
-
Rezolve AI raises $250 million in registered direct offering
-
Rezolve Ai Announces $250 Million Registered Direct Offering led by Existing and New Fundamental Institutional Investors
-
CommVault Systems (CVLT) Reiterated at Neutral by Cantor Fitzgerald Ahead of F3Q26
-
JFrog (FROG) Reiterated at Overweight by Cantor Fitzgerald: Sustained Growth Expected
-
CrowdStrike (CRWD) Reiterated at Overweight by Cantor Fitzgerald: Acquiring Seraphic
-
Alphabet (GOOGL) Reiterated at Neutral by Cantor Fitzgerald Ahead of Feb EU Deadline
-
Freshworks (FRSH) Reiterated at Overweight by Cantor Fitzgerald: An Idea for 2026
-
EastGroup Properties (EGP) Reiterated at Overweight by Cantor Fitzgerald Ahead of 4Q25
-
Douglas Emmett (DEI) Reiterated at Neutral by Cantor Fitzgerald After Model Update
-
MKS Instruments (MKSI) Reiterated at Overweight by Cantor Fitzgerald" EPS Upside Likely
-
Millennial Potash announces $15.25 million private placement offering
-
Millennial Announces "Bought Deal" Private Placement Life Offering for Proceeds of $15,250,000
-
Form 424B3 Cantor Fitzgerald Income
-
Form 424B3 Cantor Fitzgerald Income
-
Riot Platforms (RIOT) PT Raised to $31 at Cantor Fitzgerald
-
Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald
-
Cabaletta Bio (CABA) Reiterated at Overweight by Cantor Fitzgerald
-
Belite Bio (BLTE) Reiterated at Overweight by Cantor Fitzgerald
-
Arrowhead Pharma (ARWR) Reiterated at Overweight by Cantor Fitzgerald
-
ArriVent BioPharma (AVBP) Reiterated at Overweight By Cantor Fitzgerald
-
Apellis Pharmaceuticals (APLS) Reiterated at Overweight by Cantor Fitzgerald
-
Alnylam Pharmaceuticals (ALNY) Reiterated at Neutral by Cantor Fitzgerald
-
Vera Therapeutics (VERA) Reiterated at Overweight by Cantor Fitzgerald
-
Eupraxia Pharmaceuticals (EPRX) PT Raised to $19 at Cantor Fitzgerald
-
DBV Technologies (DBVT) Reiterated at Overweight by Cantor Fitzgerald
-
Abeona Therapeutics (ABEO) Reiterated at Overweight by Cantor Fitzgerald
-
Skye Bioscience (SKYE) Reiterated at Neutral by Cantor Fitzgerald
-
Chesapeake Gold Announces Filing of Prospectus Supplement in Connection with Previously Announced $15 Million Bought Deal Public Offering
-
Orchid Island Capital Announces Estimated Fourth Quarter 2025 Results and December 31, 2025 RMBS Portfolio Characteristics
-
Cantor Fitzgerald on TG Therapeutics (TGTX): 'Stock is at a very attractive valuation right now'
-
Micron Technology (MU) PT Raised to $450 at Cantor Fitzgerald: Margins Might Be Higher
-
Water Street Healthcare Partners Invests in Pillr Health
-
Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald: PT Conservative
-
uniQure (QURE) Reiterated at Overweight by Cantor Fitzgerald: FDA Feedback Key
-
Phathom Pharmaceuticals (PHAT) Reiterated at Overweight at Cantor Fitzgerald
-
Annexon Biosciences (ANNX) Reiterated at Overweight by Cantor Fitzgerald
-
Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald
-
Axsome Therapeutics (AXSM) Reiterated at Overweight by Cantor Fitzgerald
-
MindMed (MNMD) Reiterated at Overweight by Cantor Fitzgerald: Will Outperform
-
Cantor Fitzgerald Downgrades Arthur J. Gallagher (AJG) to Neutral
-
Strive to acquire Semler Scientific in all-stock deal for bitcoin holdings
-
Strive, Inc. (Nasdaq: ASST) and Semler Scientific (Nasdaq: SMLR) Announce Shareholder Approval for Acquisition of Semler Scientific
-
BioCryst Pharma (BCRX) Reiterated at Overweight by Cantor Fitzgerald
-
Apellis Pharmaceuticals (APLS) Reiterated at Overweight by Cantor Fitzgerald
-
Netstreit (NTST) Reiterated at Iverweight by Cantor Fitzgerald: Attractive Position
-
Lexeo Therapeutics (LXEO) Reiterated at Overweight by Cantor Fitzgerald
-
Mereo BipPharma (MREO) Reiterated at Overweight by Cantor Fitzgerald: High-Risk
-
Soleno Therapeutics (SLNO) Reiterated at Overweight by Cantor Fitzgerald:Bullish

